Editors’ Choice papers in Thrombosis and Haemostasis

• References

• 1 De Caterina R, Husted S, Wallentin L. et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.
• 2 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
• 3 Husted S, de Caterina R, Andreotti F. et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111: 781-782.
• 4 Rubboli A, Faxon DP, Airaksinen KEJ. et al. The optimal management of patients on oral antico-agulation undergoing coronary artery stenting. The 10th Anniversary Overview. Thromb Hae-most 2014; 112: 1080-1087.
• 5 Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thromb Haemost 2014; 111: 189-198.
• 6 Khadzhynov D, Wagner F, Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with endstage renal disease. Thromb Haemost 2013; 109: 596-605.
• 7 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
• 8 Douxfils J, Chatelain C, Chatelain B. et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Hae-most 2013; 110: 283-294.
• 9 Gouin-Thibault I, Flaujac C, Delavenne X. et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Hae-most 2014; 111: 240-248.
• 10 Douxfils J, Dogne J-M, Mullier F. et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543-549.
• 11 Hapgood G, Butler J, Malan E. et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the He-moclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110: 308-315.
• 12 Mani H, Hesse C, Stratmann G. et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Hae-most 2013; 109: 127-136.
• 13 Douxfils J, Tamigniau A, Chatelain B. et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
• 14 Pisters R, Nieuwlaat R, Lane DA. et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013; 109: 328-336.
• 15 Skjoth F, Larsen TB, Rasmussen LH. et al. Efficacy and safety of edoxaban in comparison with dabi-gatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparisonanalysis.ThrombHaemost 2014; 111: 981-988.
• 16 Lowres N, Neubeck L, Redfern J. et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110: 213-217.
• 17 Lowres N, Neubeck L, Salkeld G. et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111: 1167-1176.
• 18 Roldan V, Marin F, Manzano-Fernandez S. Does chronic kidney disease improve the predictive value of the CHADS(2) and CHA(2)DS(2)-VASc stroke stratification risk scores for atrial fibrillation?. Thromb Haemost 2013; 109: 956-960.
• 19 Apostolakis S, Lane D, Buller H. Comparison of the CHADS(2),CHA(2)DS(2) -VASc and HASBLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with at-rial fibrillation: The AMADEUS trial. Thromb Haemost 2013; 110: 1074-1079.
• 20 Gallego P, Roldan V, Marín F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. ThrombHaemost 2013; 110: 1189-1198.
• 21 Cattaneo M. High on-treatment platelet reactivity - definition and measurement. Thromb Haemost 2013; 109: 792-798.
• 22 Saucedo JF, Angiolillo DJ, DeRaad R. et al. SWAP Investigators. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 2013; 109: 347-355.
• 23 Hohlfeld T, Saxena A, Schroer K. High on treatment platelet reactivity against aspirin by non-ste-roidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance. Thromb Hae-most 2013; 109: 825-833.
• 24 Dahlen J, Price M, Parise H. et al. Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. Thromb Haemost 2013; 109: 808-816.
• 25 Grove E, Hossain R, Storey R. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824.
• 26 Serebruany V, Fortmann S. Viewpoint: “Under-utilisation of novel antiplatelet agents - myths, generics, and economics". Thromb Haemost 2014; 112: 4-9.
• 27 Langer HF, Weber C, Gawaz M. The platelet-thrombosis and beyond. Thromb Haemost 2013; 110: 857-858.
• 28 Karshovska E, Weber C, von Hundelshausen P. Platelet chemokines in health and disease. Thromb Haemost 2013; 110: 894-902.
• 29 Blanchet X, Cesarek K, Brandt J. et al. Inflammatory role and prognostic value of platelet chemo-kines in acute coronary syndrome. Thromb Hae-most 2014; 112: 1277-1287.
• 30 Necchi V, Balduini A, Noris P. et al. Ubiquitin/pro-teasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia. Thromb Haemost 2013; 109: 263-271.
• 31 Aradi D, Komócsi A, Vorobcsuk A. et al. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analy-sis. Thromb Haemost 2013; 109: 93-101.
• 32 Quinderé AL, Benevides NM, Carbone F. et al. Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrom-bosis. Thromb Haemost 2014; 111: 634-646.
• 33 de Boer OJ, Li X, Teeling P. et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 2013; 109: 290-297.
• 34 Andrews RK, Arthur JF, Gardiner EE. Neutrophil extracellular traps (NETs) and the role of platelets in infection. Thromb Haemost 2014; 112: 659-665.
• 35 Geddings JE, Mackman N. New players in haemo-stasis and thrombosis. Thromb Haemost 2014; 111: 570-574.
• 36 Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost 2013; 109: 416-420.
• 37 Carestia A, Rivadeneyra L, Romaniuk MA. et al. Functional responses and molecular mechanisms involved in histone-mediated platelet activation. Thromb Haemost 2013; 110: 1035-1045.
• 38 Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb Haemost 2013; 109: 399-406.
• 39 Goddard LM, Iruela-Arispe ML. Cellular and molecular regulation of vascular permeability. Thromb Haemost 2013; 109: 407-415.
• 40 Ehling J, Lammers T, Kiessling F. Non-invasive imaging for studying anti-angiogenic therapy effects. Thromb Haemost 2013; 109: 375-390.
• 41 Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost 2013; 109: 391-398.
• 42 Asare Y, Shagdarsuren E, Schmid JA. et al. En-dothelial CSN5 impairs NF-kB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost 2013; 110: 141-152.
• 43 Manthey HD, Cochain C, Barnsteiner S. et al. CCR6 selectively promotes monocyte mediated inflammation and atherogenesis in mice. Thromb Haemost 2013; 110: 1267-1277.
• 44 Roldán V, Arroyo AB, Salloum-Asfar S. et al. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost 2014; 112: 781-788.
• 45 Kaudewitz D, Lee R, Willeit P. et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110: 609-615.
• 46 Badrnya S, Baumgartner R, Assinger A. Smoking alters circulating plasma microvesicle pattern and microRNA signatures. Thromb Haemost 2014; 112: 128-136.
• 47 Nencioni A, da Silva RF, Fraga-Silva RA. et al. Ni-cotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2014; 111: 308-322.
• 48 Vaezzadeh N, Ni R, Kim PY. et al. Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. Thromb Haemost 2014; 112: 412-418.
• 49 Xu Y, Cai TQ, Castriota G. et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014; 111: 694-704.
• 50 Lei X, Reheman A, Hou Y. et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014; 111: 279-289.
• 51 Nieuwenhuizen L, Roosendaal G, Mastbergen SC. et al. Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice. Thromb Hae-most 2014; 112: 1044-1050.
• 52 Orriols M, Guadall A, Galán M. et al. Lysyl oxidase (LOX) in vascular remodelling. Insight from a new animal model. Thromb Haemost 2014; 112: 812-824.
• 53 Sala F, Aranda JF, Rotllan N. et al. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost 2014; 112: 796-802.